Literature DB >> 31675132

Predictors of Mortality in HPV-Associated Oropharynx Carcinoma Treated With Surgery Alone.

Mary Han1,2, Gaelen B Stanford-Moore1, Andrew R Larson1, David W Schoppy3, David M Cognetti4, Arjun S Joshi5, Jeffery J Houlton6, William R Ryan3.   

Abstract

OBJECTIVE: Survival outcomes for human papillomavirus-associated oropharynx squamous cell carcinoma (HPV + OPSCC) treated with surgery alone are unclear. To increase understanding, we assessed overall survival (OS) outcomes using the national cancer database (NCDB).
METHODS: We conducted a retrospective analysis of OS of 736 NCDB HPV + OPSCC patients who underwent surgery alone from 2010 to 2014 using univariate and multivariate analyses and the Kaplan-Meir method.
RESULTS: Multivariable analysis found the following independent risk factors for death: American Joint Commission on Cancer (AJCC) 8th edition pathologic stage(p)N2 versus pN0 disease (hazard ratio [HR], 5.5; P = 0.000006), macroscopic extranodal extension (ENE) versus non-ENE (HR, 4.9; P < 0.02), a positive lymph nodes (LN) percentage of ≥10% (HR, 4.2; P = 0.0002), and five or more positive LNs (HR, 4.9; P = 0.00004). Three-year OS was significantly worse for AJCC 8th edition pN2 versus pN0 but not for 7th edition pN2 versus pN0 disease. Five-year OS was significantly worse for positive versus negative surgical margins, AJCC 8th edition stage II versus I, and either microscopic or macroscopic ENE versus non-ENE positive LNs. For 523 (71%) AJCC 8th edition stage I patients and for 283 (38%) patients who were pT1-T2, with negative margins, pN0-N1, with ≤4 pathologic LNs, without ENE, and with >20 LNs removed during neck dissection, the 3-year OS rates were 93% and 95%, respectively, and the 5-year OS rates were 91% and 95%, respectively.
CONCLUSION: In the context of the lack of detail and possible inaccuracies found in the NCDB, surgery alone for AJCC 8th edition stage I HPV + OPSCC, particularly pT1-T2, pN0-N1 with ≤4 pathologic LNs, without ENE, and with negative surgical margins has a high OS. LEVEL OF EVIDENCE: 4 Laryngoscope, 130:E423-E435, 2020.
© 2019 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  National Cancer Database; human papilloma virus; neck; neck dissection; oropharyngeal carcinoma; oropharynx; oropharynx cancer; overall survival; risk factors for death; surgery alone

Mesh:

Year:  2019        PMID: 31675132     DOI: 10.1002/lary.28344

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  5 in total

1.  Transoral robotic surgery adoption and safety in treatment of oropharyngeal cancers.

Authors:  Jamie R Oliver; Michael J Persky; Binhuan Wang; Umamaheswar Duvvuri; Neil D Gross; Alec E Vaezi; Luc G T Morris; Babak Givi
Journal:  Cancer       Date:  2021-11-11       Impact factor: 6.921

Review 2.  Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma of the Tonsil versus Base of Tongue: A Systematic Review and Meta-Analysis.

Authors:  Nicolas S Poupore; Tiffany Chen; Shaun A Nguyen; Cherie-Ann O Nathan; Jason G Newman
Journal:  Cancers (Basel)       Date:  2022-08-08       Impact factor: 6.575

3.  Adjuvant Radiotherapy in Surgically Treated HPV-Positive Oropharyngeal Carcinoma with Adverse Pathological Features.

Authors:  Shady I Soliman; Farhoud Faraji; John Pang; Loren K Mell; Joseph A Califano; Ryan K Orosco
Journal:  Cancers (Basel)       Date:  2022-09-17       Impact factor: 6.575

4.  The accuracy of clinical neck staging for p16-positive and negative oropharyngeal cancer and its therapeutic implications.

Authors:  Timon Hussain; Kruthika Thangavelu; Cornelius Kürten; Lisa Galland; Benedikt Höing; Eric Deuss; Stefan Mattheis; Stephan Lang; Cornelius Deuschl; Michael Forsting; Nils Dörner
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-07-04       Impact factor: 3.236

Review 5.  A review of the 8th edition of the AJCC staging system for oropharyngeal cancer according to HPV status.

Authors:  Piotr Machczyński; Ewa Majchrzak; Patryk Niewinski; Joanna Marchlewska; Wojciech Golusiński
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-04-27       Impact factor: 3.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.